Answers · Valuation & Worth
Do patents increase our 409A or startup valuation?
Updated June 2026
The short answer
Two different questions with two different answers. For fundraising, yes: published academic studies commonly associate a startup's first granted patent with materially better outcomes, with funding-likelihood lifts cited roughly in the 45 to 75 percent range. For your 409A, the effect is usually marginal, and founders often should not want it anyway, since a higher 409A raises the strike price on employee options.
Patents move valuation when they are legible to the people setting it. An investor can underwrite a documented portfolio with a stated methodology; nobody can underwrite a 'patent pending' bullet on a slide.
How a 409A appraiser actually treats patents
A 409A values your common stock for option-pricing compliance, using income, market, and asset approaches at the company level. Patents enter indirectly, through the revenue forecast they protect and as qualitative support for the company's position, but a 409A provider will rarely assign your patents a standalone line-item value. The 409A is also a tax document, so the precise treatment belongs with your appraisal firm and accountants. What ipCG provides is the IP-side analysis those professionals can rely on, not the tax opinion itself.
There is also a strategic wrinkle founders sometimes miss: the 409A sets the option strike price, so a number pushed higher by aggressive IP claims makes employee equity more expensive. The place you want patents recognized is the preferred-round negotiation and the exit, where higher is better.
Where patents genuinely move startup value
Priced rounds, acquisitions, and lending. The published research is consistent in direction: studies commonly find patent-holding startups raise more, survive longer, and exit better, with some estimates associating each patent with roughly a million dollars of additional valuation in funded companies, though averages like that hide enormous variance and say nothing about your specific claims. The mechanism is defensibility: a portfolio that credibly blocks fast followers changes an investor's downside math.
The effect is strongest where imitation is the main risk, in biotech, hardware, and deep tech, and weaker where execution speed dominates. In every case the lift goes to portfolios an investor can actually evaluate: patents mapped to the product, assignments recorded, and a valuation with stated assumptions.
What to prepare before the raise
Three things, in order of cost. First, hygiene: every founder, employee, and contractor assignment executed and recorded, because this is the first thing diligence checks and the cheapest thing to fix early. Second, a patent-to-product map showing what the portfolio actually protects. Third, where IP is central to the story, an independent valuation, so the conversation starts from your documented number instead of an investor's skepticism.
Related questions
Will filing more patents raise our 409A?
Usually only at the margin, through the business forecast, and a higher 409A raises your employees' option strike price. Ask your 409A provider how they would treat it; file patents for competitive and exit value, not to move this particular number.
Do provisional applications count for anything?
They establish a priority date and signal a functioning IP process, but investors discount them heavily as standalone assets since claims do not exist yet. What earns credit is the conversion plan and the quality of the underlying disclosures.
Our investors say they ignore patents. Are they right?
Sector-dependent. In seed-stage SaaS, execution usually dominates and they are mostly right. In biotech, hardware, and deep tech, the published funding data argues otherwise, and the same investors who dismiss patents at the pitch will scrutinize them hard in exit diligence.
Who should value our IP before a raise?
An IP consultancy builds the portfolio valuation and strength analysis; your 409A firm and accountants own the tax-facing numbers. The two work from the same underlying analysis, which is the arrangement we support most often.
Make the portfolio legible before the term sheet
If IP is part of your raise narrative, get it documented before diligence starts. Tell us your timeline; the discovery call is free and the proposal is fixed-price.
Talk with Our TeamRelated
ipCapital Group is a consultancy, not a law firm, and nothing on this page is legal advice. Dollar figures on this page are typical market ranges for professional IP services, drawn from published sources and industry experience across a variety of providers. They are not an ipCG quote or rate card; every ipCG engagement is individually scoped and priced. See how our pricing works.